Medical Device Procurement in Taiwan: A Supplier's Guide [2026]

Taiwan has a highly developed healthcare system with universal National Health Insurance (NHI) coverage and a medical device market valued at approximately USD 5 billion. With world-class medical centers, high technology adoption rates, and a well-defined regulatory framework, Taiwan is an attractive market for medical device suppliers. The Taiwan FDA (TFDA) regulatory process is transparent and increasingly harmonized with international standards.

Regulatory authority and approval pathway

The Taiwan Food and Drug Administration (TFDA), under the Ministry of Health and Welfare (MOHW), regulates medical devices under the Medical Devices Act:

• Device classification: Taiwan uses a three-class system (Class I, II, III) based on risk.
• Registration: Class I devices require listing notification. Class II and III devices require pre-market approval (PMA) with technical documentation review by TFDA. Class III devices require clinical evidence review.
• GMP compliance: Taiwan's GMP requirements align with ISO 13485. TFDA accepts QMS audit certificates from recognized international bodies, but may conduct its own audits for higher-risk devices.
• Local agent: Foreign manufacturers must appoint a Taiwan-based agent (local license holder) who is responsible for regulatory submissions and post-market activities.
• Reference regulatory approval: TFDA accepts FDA 510(k) clearance, CE marking, and approvals from other reference regulators to expedite review, particularly for Class II devices.

Key procurement platforms and channels

• Government e-Procurement System: Taiwan's central government procurement portal where public hospital tenders are published.
• NHI reimbursement: Devices must be listed on the NHI reimbursement schedule to be used in NHI-covered treatments. The National Health Insurance Administration (NHIA) sets reimbursement prices based on health technology assessment and international reference pricing.
• Medical center procurement: Taiwan's 19 medical centers (including National Taiwan University Hospital, Chang Gung Memorial Hospital, and Taipei Veterans General Hospital) conduct their own procurement for high-value equipment.
• Joint Purchasing Alliance: Some hospital groups use joint purchasing to negotiate volume discounts.
• Private clinics and specialty centers: Taiwan has a large private clinic sector that procures independently.

Compliance requirements for tenders

• TFDA license: Valid device license is mandatory for all procurement.
• Traditional Chinese-language documentation: Labeling, IFU, and tender submissions must be in Traditional Chinese (not Simplified).
• CNS standards: Chinese National Standards (CNS) compliance may be required for certain device categories.
• Clinical evidence: Hospitals value clinical data from Taiwanese or East Asian patient populations.
• After-sales service commitment: Tenders typically require detailed service level agreements including response times and spare parts availability in Taiwan.

Market size and opportunity

• Advanced surgical technology: Taiwan medical centers are early adopters of robotic surgery, image-guided therapy, and minimally invasive devices.
• Aging population: Taiwan's rapidly aging demographics (projected 20% elderly by 2026) drive demand for chronic disease management and rehabilitation devices.
• Smart hospitals: Government initiatives promoting smart hospital technologies create procurement opportunities for IoT-enabled devices and health IT.
• Dental devices: Taiwan has one of the highest dental visit rates globally, creating strong demand for dental devices and materials.

Tips for foreign suppliers

1. Leverage reference approvals: If you have FDA or CE marking, use TFDA's expedited review pathway to shorten registration timelines.
2. Secure NHI listing: Without NHI reimbursement, hospital adoption is limited. Engage NHIA pricing discussions early in your market entry planning.
3. Build relationships with medical center KOLs: Taiwan's 19 medical centers influence purchasing decisions across the healthcare system. KOL relationship tools accelerate this process.
4. Choose a capable local agent: Your Taiwanese agent manages regulatory submissions and often serves as your distributor. Select one with both TFDA expertise and hospital access.
5. Automate tender tracking: MedStrato consolidates Taiwanese procurement opportunities alongside other APAC markets. Book a demo to learn more.